Abstract
Hodgkin lymphoma is characterized by CD30 overexpression and downstream NF-κB pathway activation in Hodgkin/Reed-Sternberg (H/RS) cells. Accordingly, CD30 and its aberrant downstream signaling have been investigated as potential treatment targets for the disease. Given that H/RS cells are surrounded by a variety of immune cells that constitute a unique inflammatory and immunoinhibitory microenvironment, efforts have also been made to treat the disease by reversing the abnormal tumor immune milieu. In recent years, a CD30 antibody-drug conjugate and immune checkpoint inhibitors have been approved for the treatment of Hodgkin lymphoma and have demonstrated remarkable treatment efficacy. These new agents have not only contributed to improved survival of patients refractory to conventional chemotherapy but have also enabled further understanding on the molecular pathogenesis of Hodgkin lymphoma in relation to the key signaling of the PD-1 and JAK/STAT pathways.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
